Cells receive signals
GLP‑1 stands for glucagon-like peptide-1, a hormone released by the body. GLP‑1 receptor agonists activate the receptor and mimic part of the natural signal.
World Health Organization Q&AGLP‑1 GUIDE Receptor signaling and evidence
Understanding GLP‑1
Start with a signal released by the gut and work through a U.S. FDA safety communication. Identify where the signal acts and what the data supports.
Signaling pathway
- The gut releases GLP‑1
- The GLP‑1 receptor receives the signal
- The cell responds
01 Mechanism
What roles do receptors, RNA, and DNA play?
To distinguish these mechanisms, look at what each intervention acts on directly.
Cells transmit and use genetic information
Messenger RNA carries the instructions for making proteins. Some RNA therapies affect how cells use this information.
U.S. National Library of MedicineCells store genetic information
Genome editing directly changes a DNA sequence. Gene therapy includes several approaches, including genome editing.
U.S. National Library of Medicine02 Regulatory evidence
FDA requires a labeling update on NAION risk
NAION stands for non-arteritic anterior ischemic optic neuropathy, a rare and serious disorder of the optic nerve.
U.S. FDA · Drug safety communication
GLP‑1 receptor agonists and the potential risk of NAION
The FDA required GLP‑1 receptor agonist application holders to add information about a possible increase in NAION risk to the Warnings and Precautions section of U.S. drug labeling.
- Published
- Archived here
- Jurisdiction
- United States
- What the FDA observed
- The FDA pooled 126 randomized trials and identified 15 possible cases of NAION. The pooled incidence was 6.4 cases per 100,000 person-years in the GLP‑1 receptor agonist group and 3.8 per 100,000 person-years in the comparator group. The comparator group received a placebo or another class of glucose-lowering medication. Person-years add up observation time across participants. The FDA also reviewed animal and postmarketing data.
- What remains uncertain
- The possible mechanism remains unclear. Risk for individual products, populations, and patients needs separate evaluation. Consult Chinese regulatory sources for the status of drug labels in China.
03 Reading exercise
Which statement does the source support?
Review the scope of the FDA communication and its pooled data, then reveal the answer.
- The U.S. FDA required drug labels to include the potential risk of NAION.
- The FDA gave a NAION risk estimate for each specific product.
Reveal the answer
A is correct. The communication reported a regulatory action and pooled findings. Product-specific risk requires evidence about that product.